You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Harvard Business School
Mallinckrodt
McKesson
AstraZeneca

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,183,034


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,183,034 protect, and when does it expire?

Patent 10,183,034 protects VABOMERE and is included in one NDA.

This patent has thirty-five patent family members in twenty-one countries.

Summary for Patent: 10,183,034
Title:Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives
Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.
Inventor(s): Hirst; Gavin (San Diego, CA), Reddy; Raja (San Diego, CA), Hecker; Scott (Del Mar, CA), Totrov; Maxim (San Diego, CA), Griffith; David C. (San Marcos, CA), Rodny; Olga (Mill Valley, CA), Dudley; Michael N. (San Diego, CA), Boyer; Serge (San Diego, CA)
Assignee: Rempex Pharmaceuticals, Inc. (Lincolnshire, IL)
Application Number:15/935,782
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 10,183,034

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Rempex Pharms VABOMERE meropenem; vaborbactam POWDER;INTRAVENOUS 209776-001 Aug 29, 2017 RX Yes Yes   Start Trial   Start Trial TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,183,034

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011289615   Start Trial
Brazil 112013003045   Start Trial
Canada 2807546   Start Trial
Chile 2013000399   Start Trial
China 103180328   Start Trial
Colombia 6680667   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Express Scripts
Colorcon
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.